BTMD

Biote Corp. 10-Q Summary: Q3 2025

Business Context and Reporting Period

This summary covers the quarterly period ended September 30, 2025. Biote Corp. (BTMD) operates as a single segment business providing the "Biote Method," a platform for hormone optimization using bioidentical hormone replacement pellet therapy. The company trains physicians, provides practice management software, and sells bioidentical hormone pellets and dietary supplements. The company is classified as an accelerated filer and an emerging growth company.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: Q3 2025 revenue decreased 6.7% year-over-year. This was driven by a $4.0 million decrease in pellet procedure revenue due to reduced new clinic additions and lower procedure volumes, partially offset by a $0.9 million increase in dietary supplement sales.
• Profitability Improvement: Despite revenue declines, the company reported a net income of $9.22 million in Q3 2025 compared to $12.66 million in Q3 2024. On a year-to-date basis, the company swung from a net loss of $3.44 million in 2024 to a net income of $28.98 million in 2025.
• Cost Management: Cost of revenue decreased 11.4% in Q3, outpacing the revenue decline, largely due to cost savings from the vertical integration of Asteria Health (acquired in 2024).
• SG&A Increase: Selling, general, and administrative expenses increased 9.3% in Q3, primarily due to the timing of the annual marketing event shifting to Q3 2025 and increased marketing spend on Amazon.
• Non-GAAP Adjustments: The year-to-date net income includes a significant non-cash gain of $11.78 million from the change in fair value of earnout liabilities, driven by a 51.4% decrease in the company's stock price during the period.

Guidance, Outlook, and Risks

• Management Commentary: Management highlighted a slowdown in new clinic additions and procedure volumes. However, they noted continued growth in dietary supplement sales via Amazon and cost efficiencies from manufacturing integration. A workforce reduction of approximately 15 roles (7.2% of workforce) was completed in Q2 2025 to improve efficiency.
• Liquidity: The company maintains $28.05 million in cash and $50.0 million in available revolving credit. Management believes this is sufficient to fund operations for the next 12 months.
• Legal Contingencies:
  • Right Value Litigation: Settled for $5.0 million; $3.5 million paid in Q1 2025, with $1.5 million remaining in accrued liabilities.
  • Donovitz Litigation: A subsequent event (Nov 3, 2025) disclosed an agreement to repurchase remaining Class V voting stock for $18.5 million in Jan 2026, settling pending legal matters.
  • Cindy Latch Litigation: Pending trial scheduled for April 2026 regarding misappropriation of name, image, and likeness.
• Internal Controls: The company disclosed a material weakness in internal controls over financial reporting related to the control environment and IT general controls. This weakness has not been remediated as of September 30, 2025.

Investor Verification Checklist

• Earnout Liability Volatility: Verify the impact of stock price fluctuations on the "Gain from change in fair value of earnout liabilities," which significantly boosted YTD net income but is non-cash.
• Share Repurchase Obligations: Confirm the status of the forward share repurchase liabilities ($40.46 million total) and the subsequent Nov 2025 settlement with Dr. Donovitz requiring an $18.5 million payment in Jan 2026.
• Inventory Levels: Review the increase in inventory ($16.45 million vs $14.85 million prior year-end) and the associated allowance for obsolete/expired pellets ($2.14 million) given the slowdown in procedure volumes.
• Internal Control Remediation: Monitor the progress of remediation efforts for the material weakness in internal controls, which affects the reliability of financial reporting.
• Legal Settlements: Track the cash outflow for the remaining $1.5 million Right Value settlement and the upcoming $18.5 million Donovitz settlement.